Inhibitory konwertazy czy sartany u pacjentów z cukrzycą? Najnowsza meta-analiza

Jun Cheng i wsp. Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes Mellitus. A Meta-analysis , LINK: JAMA Intern Med. Published online

Conclusions and Relevance: Angiotensin-converting enzyme inhibitors reduced all-cause mortality, CV mortality, and major CV events in patients with DM, whereas ARBs had no benefits on these outcomes. Thus, ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population.

Opracowane na podstawie: JAMA / 31 marca 2014